• self reported weekly alcohol consumption [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  
• self reported weekly alcohol craving [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  
• weekly ratings of negative/positive psychotic symptoms [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  
• baseline and end of treatment cognitive functioning measures [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  

• weekly drug use [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  
• baseline and end of treatment quality of life [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  
• baseline and end of treatment neurophysiological measures [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  

Drug: Glycine
Glycine, 0.8 gr per kg given in two daily doses

OBJECTIVE: Schizophrenia affects about 1% of the general population and is a highly disabling disease. Additionally, the rate of alcohol dependency for patients with schizophrenia is very high. There are no established treatments for alcohol dependency and negative symptoms in schizophrenia. This study will examine whether the addition of glycine to neuroleptic medications will help patients with schizophrenia and alcoholism decrease their drinking as well as improve negative symptoms.

RESEARCH PLAN: An abnormality of the glutamate neurotransmitter system has been hypothesized for both alcoholism and schizophrenia. Studies suggest that the amino acid glycine may improve alcohol dependency and symptoms of schizophrenia by acting on the N methyl D aspartate (NMDA) glutamate receptor. Glycine causes reversal of the effects of ethanol in animal studies and improves mood, social withdrawal and other so called "negative symptoms" of schizophrenia. Consequently, the use of glycine by patients with schizophrenia and alcohol dependency may potentially decrease alcohol craving and alcohol consumption and also improve certain symptoms of schizophrenia. The potential of glycine to improve both alcohol dependency and negative symptoms could represent an important step in the improvement of the quality of life for patients with schizophrenia.

METHODOLOGY/FINDINGS/RESULTS: In order to test this hypothesis, we will use a double blind, placebo controlled study and measure the number of drinks, the degree of craving for alcohol and symptoms of schizophrenia among other parameters. Our principal approach to analyses of medication effectiveness will be the application of the linear mixed effect model. The linear mixed effect model permits a flexible approach for studying change in individuals through time as a random effect, and does not require all patients to have data at all measured points. Our principal model of analysis includes treatment (placebo or glycine), as between subject factor, and time, as within subject factor. Compliance will be also included as a time varying independent variable. This project continues to recruit subjects.